cbdMD, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by cbdMD, Inc. on March 15, 2022, covering events that occurred on March 11, 2022. The filing details the results of the company's 2022 Annual Meeting of Shareholders and subsequent board of directors appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Corporate Actions
The primary material event reported is the conclusion of the 2022 Annual Meeting of Shareholders. Key outcomes include:
- Shareholder Participation: Of 58,546,720 shares outstanding, 25,274,348 shares (43%) were represented, constituting a quorum.
- Proposal 1 (Director Elections): All six director nominees were elected. Notably, Bakari Sellers and Peter J. Ghiloni received significant "Against" votes (6,031,524 and 3,248,659 respectively) compared to other nominees, though both were approved.
- Proposal 2 (Auditor Ratification): The appointment of Cherry Bekaert LLP as the independent registered public accounting firm was ratified with 25,186,445 "For" votes.
Management Commentary, Risks, and Unusual Items
Following the annual meeting, the Board of Directors reappointed key executive officers and established board committee memberships:
- Executive Appointments: Martin A. Sumichrast was reappointed as Chairman of the Board and co-Chief Executive Officer. R. Scott Coffman was reappointed as co-Chief Executive Officer and President. T. Ronan Kennedy was reappointed as Chief Financial Officer, Chief Operating Officer, Secretary, and Treasurer.
- Committee Appointments:
- Audit Committee: William F. Raines, III (Chairman), Bakari Sellers, Scott G. Stephen, and Peter J. Ghiloni.
- Compensation, Corporate Governance and Nominating Committee: Bakari Sellers (Chairman), William F. Raines, III, and Peter J. Ghiloni.
The filing does not disclose specific new risks, contingencies, or unusual items beyond the standard governance updates.
Investor Verification Checklist
- Verify the specific reasons for the high volume of "Against" votes cast for directors Bakari Sellers and Peter J. Ghiloni by reviewing the definitive proxy statement (Schedule 14A) filed on January 27, 2022.
- Confirm the continued tenure of the co-CEO structure (Sumichrast and Coffman) and its impact on strategic decision-making.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.